News | Embolic Protection Devices | September 07, 2017

Protembis Announces Successful First-in-Human Use of ProtEmbo Cerebral Protection System in European Trial

Intra-aortic filter device designed to cover all three aortic side branches to deflect embolic material from the brain during TAVR

Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial

September 7, 2017 — Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a transcatheter aortic valve replacement (TAVR) procedure. The ProtEmbo System is an intra-aortic filter device that deflects embolic material arising during TAVR away from the brain.

Darren Mylotte, M.D., and his team at Galway University Hospital, Ireland, performed the first-in-human procedure with the ProtEmbo System. He commented: “Over the next 10 years, TAVR procedures are expected to increase fourfold. With TAVR shifting to younger and lower-risk patients, cerebral protection becomes even more important. Clinical data from two recent studies of intermediate-risk patients undergoing TAVR suggest 30-day stroke risk as high as 5.5 percent. It is therefore critically important that we have a cerebral-focused protection device that will reduce the frequency of embolic events. The ProtEmbo System shows tremendous promise in reaching this clinical objective – first-in-human use of the device was safe and feasible.”

The objective of the current ongoing European trial is to demonstrate the safety and feasibility of the ProtEmbo System when used to provide embolic protection during TAVR. It was successfully deployed via the left radial artery across all three branches of the aortic arch for the duration of the TAVR procedures. The procedures were conducted under conscious sedation. On completion of the valve implant, the system was safely withdrawn without difficulty. None of the patients experienced a stroke event and there were no other device-related adverse events.

Features and benefits of the ProtEmbo include:

  • Low-profile access via left radial artery (6Fr guiding sheath);
  • Best access route: no interference with TAVR catheter or accessories;
  • Simple, quick and reliable deployment;
  • Complete coverage of all three aortic side branches;
  • Deflection of microparticles, as tiny as 60 microns;
  • Suitable for a wide variety of aortic arch anatomies; and
  • Heparin coating for optimal biocompatibility.

Renu Virmani, M.D., president and medical director at CVPath Institute, Gaithersburg, Md., commented: “Our preclinical work with the ProtEmbo System prior to this clinical trial resulted in no safety or biocompatibility concerns. These initial findings from Europe now confirm our previous results. Despite the small pore size of the ProtEmbo System, there is no thrombus formation on the filter. This is promising because it may enable physicians to deflect even smaller particles away from the brain.”

Watch a video animation showing how the ProtEmbo system is deployed.

For more information: www.protembis.com

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init